How to Get Compounded Semaglutide Without Insurance in 2026

*This article is for informational purposes only. It is not medical advice. Consult a licensed healthcare provider before starting any medication or treatment program.*

---

If you are exploring compounded semaglutide without insurance, the price of brand-name options has probably already given you pause. Wegovy and Ozempic carry list prices of $800 to $1,300 per month without insurance coverage. For most people paying out of pocket, that number is simply not realistic.

Here is what a lot of people do not realize: insurance is not the only path to semaglutide treatment. Compounded semaglutide, available through licensed telehealth platforms, has made medically supervised GLP-1 treatment accessible at a fraction of the brand-name price. You do not need an insurance plan that covers weight loss medications to get started. You need a licensed provider who can evaluate whether treatment is right for you, and a pharmacy that can fill your prescription.

This guide explains what compounded semaglutide costs without insurance, what is typically included, and what to look for when choosing a provider.

---

Why Insurance Rarely Covers Compounded Semaglutide

Understanding the coverage gap helps put the cost picture in context.

Brand-name coverage is inconsistent. Even for FDA-approved semaglutide products like Wegovy, insurance coverage for weight loss is far from guaranteed. According to data from the Obesity Medicine Association, fewer than 30 percent of commercial insurance plans cover anti-obesity medications at all. Many that do require prior authorization, documented BMI thresholds, and failed attempts at other interventions before approving treatment.

Compounded medications sit outside the coverage framework entirely. Compounded semaglutide is not an FDA-approved drug. It is prepared by a licensed compounding pharmacy based on an individual prescription from a licensed provider. Because it is not a standardized manufactured product, it does not appear in insurance formularies. No insurance plan covers compounded semaglutide for the same reason they do not cover custom-compounded medications generally: coverage is built around approved, standardized drugs.

This is a design gap, not a failure. The insurance system was not built to handle this category. And for patients who cannot access or afford brand-name products, it means the question shifts from "what will my insurance cover?" to "what will this cost me directly?"

---

The Real Cost of Compounded Semaglutide Without Insurance

The direct-pay market for compounded semaglutide has become competitive. Here is a realistic picture of what you will encounter.

Price range across providers: Most telehealth platforms offering compounded semaglutide charge between $159 and $350 per month. The variation comes from what is included, pharmacy relationships, and business model differences.

What affects your price:

• Dose level. Patients typically start at lower doses during the titration phase and increase over time. Some providers charge the same flat rate across all doses; others adjust pricing as you escalate.
• What is bundled. A low headline price that excludes provider consultation fees, lab work, or follow-up visits is not a low price. Read carefully before comparing numbers.
• Pharmacy source. 503A compounding pharmacies prepare medications per individual prescription and may vary in cost. 503B outsourcing facilities operate under FDA oversight and produce medications at scale, which can affect pricing and quality consistency.
• Form factor. Compounded semaglutide is available as a subcutaneous injection or, more recently, as an oral formulation. Oral versions typically carry a different price point than injectable formulations.

Prescriva's pricing: Prescriva offers compounded semaglutide starting at $159 per month, all-inclusive. That means your medical consultation, your prescribed medication, and shipping are covered in one flat rate. No separate consultation fee, no surprise billing at the pharmacy.

---

How Telehealth Changes the Access Equation

Before telehealth, getting a GLP-1 prescription without insurance meant finding an obesity medicine specialist willing to see you out-of-pocket, paying separately for that consultation, then paying a specialty pharmacy for the medication, and returning for follow-up visits billed at each encounter. The friction was significant, even for people who could afford the total cost.

Telehealth platforms have simplified every step of that process.

Online medical evaluation. You complete a health assessment online, including your health history, current medications, weight history, and goals. A licensed provider reviews your information and determines whether GLP-1 treatment is medically appropriate for you. This replaces an in-person office visit.

Prescription and pharmacy coordination. If your provider determines treatment is appropriate, they write a prescription sent directly to a licensed compounding pharmacy. The pharmacy prepares your medication based on that specific prescription.

Home delivery. Your medication ships directly to your door. Recurring shipments are coordinated automatically so you are not managing pharmacy pickups or running out between fills.

Ongoing provider access. Legitimate platforms include ongoing access to your provider or care team for questions, dose adjustments, and support. This is not a one-and-done prescription service.

This model removes most of the logistical and cost barriers that made out-of-pocket treatment impractical before.

---

What to Look for When Choosing a Provider

Not all compounded semaglutide providers are the same. Because you are paying directly and there is no insurance acting as a backstop on quality, you are responsible for evaluating the provider yourself. Here is what matters.

Pharmacy transparency. The provider should be able to tell you exactly which compounding pharmacy fulfills your prescription and confirm whether it is a 503A or 503B facility. A legitimate platform does not obscure this information.

All-in pricing. Ask specifically: does the quoted monthly price include the medical consultation, the medication, and shipping? If you have to ask three follow-up questions to get a real number, that is a signal.

Licensed providers. Your prescription must come from a licensed clinician, nurse practitioner, or other prescribing provider who holds an active license in your state. Confirm this is the case before submitting personal health information.

Ongoing support. Weight management with GLP-1 medications is a process, not a single event. You will likely need dose adjustments, guidance on managing side effects during titration, and support if your progress stalls. A provider who disappears after the first prescription is not a partner in your care.

Red flags to avoid:

• Providers that will prescribe without any medical evaluation
• Platforms claiming their compounded product is "equivalent to Ozempic or Wegovy" (it is not; compounded drugs are not FDA-approved)
• Prices that seem too good to be true without clear disclosure of what is included
• No identifiable pharmacy partner or vague descriptions of "licensed pharmacy"

---

Who Qualifies for Compounded Semaglutide

Eligibility is determined by a licensed provider based on your individual health picture. General criteria that are commonly applied include:

• BMI of 30 or higher (obesity classification)
• BMI of 27 or higher with a weight-related health condition such as type 2 diabetes, high blood pressure, or sleep apnea (overweight with comorbidities)
• Absence of contraindications, including a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
• No current pregnancy

GLP-1 medications are not appropriate for everyone. A licensed provider evaluates your specific health history and medications before making any prescribing decision. This medical review is not a formality; it is how treatment is matched to individual circumstances.

---

What Results Look Like in Practice

Published clinical research on GLP-1 receptor agonists provides useful benchmarks, with an important caveat. The STEP 1 trial, published in the *New England Journal of Medicine* ([PMID: 33567185](https://pubmed.ncbi.nlm.nih.gov/33567185/)), found that adults treated with semaglutide lost an average of approximately 15 percent of their body weight over 68 weeks compared to approximately 2.4 percent in the placebo group. The SURMOUNT-1 trial ([PMID: 35658024](https://pubmed.ncbi.nlm.nih.gov/35658024/)) reported even larger average results with tirzepatide.

These are findings from trials of branded, FDA-approved products administered under controlled research conditions. Compounded semaglutide is prepared by a licensed compounding pharmacy under a separate regulatory pathway. It is not the same product as the branded versions used in these trials and has not undergone equivalent clinical testing. Individual results on any GLP-1 program depend heavily on starting weight, dose adherence, dietary habits, physical activity, and other individual factors. Results are not guaranteed and vary from person to person.

Treatment typically includes a titration period of 4 to 8 weeks where you start at a lower dose while your body adjusts. Most people experience the most significant side effects (nausea, occasional digestive disruption) during this early phase. Effective dose management during this window is one of the most important factors in long-term adherence.

---

Starting Without Insurance at Prescriva

Prescriva connects you with licensed healthcare providers who evaluate whether compounded weight management medication is right for you. If treatment is appropriate, your provider writes a prescription filled by a licensed compounding pharmacy. Medication ships directly to your home.

The monthly cost starts at $159, all-inclusive: no hidden consultation fees, no separate pharmacy charge, no billing surprises.

Ready to explore your options? Check your eligibility at Prescriva.

---

Frequently Asked Questions

Is compounded semaglutide FDA-approved? No. Compounded semaglutide is not an FDA-approved medication. Compounded medications are prepared by licensed pharmacies based on individual prescriptions and are not reviewed by the FDA for safety, efficacy, or quality. This is different from branded FDA-approved products like Ozempic and Wegovy. A licensed provider can discuss whether compounded semaglutide is an appropriate option for your specific situation.

Can I get compounded semaglutide without seeing a doctor in person? Yes. Telehealth platforms allow licensed providers to evaluate your health history and prescribe appropriate treatment online, without an in-person office visit. All prescriptions must come from a licensed provider in your state; reputable platforms require a genuine medical evaluation before any prescription is written.

What happens if my dose needs to change? Legitimate providers include ongoing access to your care team. Dose adjustments during the titration process, or based on your progress and side effect profile, are part of a real treatment program. If a platform does not offer this, look elsewhere.

Does the $159/month price at Prescriva include everything? Yes. Prescriva's monthly pricing includes your medical consultation, your prescribed compounded semaglutide medication, and shipping. There are no separate provider fees or pharmacy charges.

How is compounded semaglutide different from Ozempic or Wegovy? Ozempic and Wegovy are brand-name FDA-approved semaglutide products manufactured by Novo Nordisk. Compounded semaglutide is prepared by a licensed compounding pharmacy for an individual patient based on a specific prescription. It is not the same product as Ozempic or Wegovy. Compounded medications are not FDA-approved, not equivalent to the branded products, and not interchangeable with them. Both types require a valid prescription from a licensed provider.

---

Disclaimers

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare provider before starting any medication or treatment program.

Compounding Disclaimer: Compounded semaglutide is not an FDA-approved medication. Compounded medications are not reviewed by the FDA for safety, efficacy, or quality. Compounded semaglutide is not the same as, equivalent to, or interchangeable with FDA-approved semaglutide products (Ozempic, Wegovy, or Rybelsus).

Results Disclaimer: Individual results vary. Weight management outcomes depend on adherence to your prescribed treatment plan, diet, exercise, starting weight, and other individual health factors. Results are not guaranteed.

Provider Disclaimer: All medical services, including prescribing, are provided by independently licensed healthcare providers. Blue Oak Services LLC dba Prescriva is a management services organization and does not practice medicine or make clinical decisions.

Brand Disclaimer: Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Prescriva is not affiliated with, endorsed by, or sponsored by Novo Nordisk.

---

Sources

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *New England Journal of Medicine.* 2021;384(11):989-1002. [PMID: 33567185](https://pubmed.ncbi.nlm.nih.gov/33567185/)
2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. *New England Journal of Medicine.* 2022;387(3):205-216. [PMID: 35658024](https://pubmed.ncbi.nlm.nih.gov/35658024/)
3. Ward ZJ, et al. Projected US State-Level Prevalence of Adult Obesity and Severe Obesity. *NEJM.* 2019;381(25):2440-2450. [PMID: 31851800](https://pubmed.ncbi.nlm.nih.gov/31851800/)
4. Obesity Medicine Association. Insurance Coverage for Obesity Treatment. 2025. [oma.org]
5. FDA. Compounded Drug Products that are Copies of Commercially Available Drug Products Under Section 503A. Guidance for Industry. 2024.